12 Under-the-Radar Stocks With Massive Upside for 2024
In this piece, we will take a look at the 12 under the radar stocks with massive upside for 2024.
Editas Medicine Inc. (EDIT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 33,875 | $251,353 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $45.51 | 5,800 | Director | 22,700 | 2021-03-03 | Filing | |
| $46.27 | 25,000 | Officer, Director | 35,000 | 2021-03-02 | Filing | |
| $23.94 | 10,200 | Director | 16,900 | 2019-03-05 | Filing | |
| $38.03 | 10,000 | Director | 10,000 | 2018-05-18 | Filing | |
| $37.28 | 6,700 | Director | 6,700 | 2018-05-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.42 | 77,824 | Officer, Director | 327,470 | 2024-03-05 | Filing | |
| $9.42 | 20,327 | Officer | 141,543 | 2024-03-04 | Filing | |
| $10.90 | 103 | Officer | 74,791 | 2023-12-05 | Filing | |
| $8.21 | 695 | Officer | 74,894 | 2023-11-14 | Filing | |
| $8.40 | 139 | Officer | 75,589 | 2023-11-07 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,461,857 | $85,718,611 | 0% | |
| 2. | 7,838,969 | $79,408,756 | 0% | |
| 3. | 5,069,543 | $51,354,471 | 0% | |
| 4. | 2,392,396 | $24,236,002 | 0% | |
| 5. | 1,981,679 | $20,074,408 | 0.02% |
News See All
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript
Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.52.
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript
Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.52.
Top 11 CRISPR Stocks To Invest In
Genome editing refers to a set of technologies enabling scientists to modify an organism's DNA by adding, removing, or altering genetic material at specific locations in the genome, as defined by MedlinePlus...
12 Best Genomics Stocks To Buy Now
In this piece, we will take a look at the 12 best genomics stocks to buy now.
Editas Medicine, Inc. (NASDAQ:EDIT) Q3 2023 Earnings Call Transcript
Operator: Good morning, and welcome to Editas Medicine's Third Quarter Conference Call. All participants are now in listen-only mode.
Top 20 Genomics Companies in the World
In this piece, we will take a look at the top 20 genomics companies in the world.
Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2023 Earnings Call Transcript
Operator: Good morning and welcome to Editas Medicine's Second Quarter Conference Call. There will be a question-and-answer session at the end of this call.
10 DNA Stocks Billionaires Are Loading Up On
Genomics is the study of a complete set of DNA within an organism.
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2023 Earnings Call Transcript
Operator: Good morning, and welcome to Editas Medicine’s First Quarter Conference Call. All participants are now in a listen-only mode.
Billionaire Hedge Funds
